Ellevest Inc’s Lexicon Pharmaceuticals LXRX Stock Holding History

Ellevest Inc’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-280	Closed	-$1K	–	1501
2021 Q2	$1K	Hold	280	–	–	﹤0.01%	1168
2021 Q1	$2K	Hold	280	–	–	﹤0.01%	1064
2020 Q4	$1K	Buy	+280	New	+$534	﹤0.01%	1080

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ellevest Inc's LXRX Position: Q3 2021 in Review

Ellevest Inc sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2021, closing a stake of 280 shares — an estimated $1K sold.

Ellevest Inc first reported a position in LXRX in Q4 2020 and held it in 3 quarters. The position peaked at $2K in Q1 2021. 96 funds tracked by Wall St. Rank hold LXRX as of Q3 2021.

Ellevest Inc reported no remaining Lexicon Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Ellevest Inc sold 280 Lexicon Pharmaceuticals shares in Q3 2021, an estimated $1K.
Ellevest Inc first reported a position in Lexicon Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Ellevest Inc's Lexicon Pharmaceuticals position peaked at $2K in Q1 2021.
96 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2021.

Based on Ellevest Inc's 13F filing for Q3 2021, filed 19 Oct 2021.